Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAetna Barrett's Esophagus Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0728

    Barrett's Esophagus

    Customize your policy alerts

    Sign up for Aetna Policy 0728 alerts

    Get alerted when Policy 0728 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, investigational/experimental stance, and coding guidance for treatments and diagnostics related to Barrett's esophagus; applies to Aetna members and treating providers.

    Policy Summary
    PayerAetna
    PolicyBarrett's Esophagus
    Policy CodePolicy 0728
    Change TypeNo material clinical or coverage changes
    Effective DateOct 13, 2006
    Last ReviewAug 2, 2023
    Next Review DateAug 8, 2024
    Key ActionDocument histologic confirmation of low-grade dysplasia on two or more endoscopies at least 3 months apart to support medical necessity for radiofrequency ablation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    77.4%RFA CR-IM (AIM)
    92%CR-IM at 5y (Fleischer)
    up to 33%Recurrence after RFA
    ~13,500Cytosponge BEST3 RCT size
    MultipleExperimental/interventional list

    Coverage criteria and evidence-based positioning

    Interventions for HGD

    Covered options for confirmed high-grade dysplasia

    Interventions for HGD: For Barrett's esophagus with high‑grade dysplasia (HGD) confirmed by biopsy, any one of the following interventions is considered medically necessary: endoscopic mucosal resection (EMR), esophagectomy, fundoplication, photodynamic therapy (PDT), or radiofrequency ablation (RFA).confirmed HGD on biopsy

    Choice of therapy depends on lesion characteristics and clinical context; combined EMR plus ablation is recommended for nodular HGD.

    Evidence-based considerations for ablative therapies

    Evidence summaries and implications

    PDT evidence: Randomized phase III trial of porfimer photodynamic therapy (PDT) plus omeprazole showed higher complete HGD ablation (77% vs 39%) and lower esophageal adenocarcinoma occurrence compared with omeprazole alone.

    Overholt et al. randomized trial demonstrated PDT efficacy for HGD.

    RFA randomized evidence: Randomized sham‑controlled and long‑term follow‑up trials (AIM/Shaheen et al.) demonstrated high rates of eradication of dysplasia and intestinal metaplasia with RFA and reduced progression and fewer cancers in treated patients.

    Shaheen et al. reported CR rates and reduced progression after RFA.

    Cryotherapy evidence: Observational cohorts and systematic reviews report substantial CE‑D/CE‑IM rates with cryotherapy (including liquid nitrogen and balloon systems), but evidence is primarily nonrandomized and heterogeneous with limited long‑term comparative data.

    Cryotherapy is supported chiefly as salvage therapy after RFA failure pending RCT data.

    APC and other techniques: Argon plasma coagulation and other older thermal techniques can achieve ablation in some series, but microscopic residual disease and uncertain long‑term cancer prevention limit their routine use for BE management.

    Comparative effectiveness versus PDT/RFA is inconsistent.

    EMR role: Endoscopic mucosal resection is effective for removal and histopathologic diagnosis of visible superficial lesions; piecemeal resection of larger lesions limits margin assessment and may necessitate alternative approaches.

    EMR provides histologic staging and is combined with ablation when appropriate.

    Comparative and long‑term implications: Systematic reviews and pooled analyses suggest ablation reduces cancer incidence compared with historical cohorts, with greatest absolute benefit in HGD; evidence for routine ablation of non‑dysplastic BE is insufficient and cost‑effectiveness is uncertain.

    Wani and others highlight limitations comparing treated cohorts to natural history data.

    Ablation selection — dysplastic BE

    Covered when trial‑based selection criteria are met (evidence supports RFA for dysplastic BE in selected patients):

    RFA for dysplastic BE (trial selection criteria): Patient has Barrett's esophagus with confirmed dysplasia (LGD or HGD) documented by expert gastrointestinal pathology review; prior evaluation and acid suppression therapy (eg, PPI) documented; selection and treatment performed in settings consistent with trial protocols (expert centers, standardized surveillance and follow‑up).LGD: confirmation by expert pathology; HGD: confirmed on biopsy

    Trials required expert pathologist confirmation and documented PPI therapy; community results may differ from trial outcomes.

    Ablation — non-dysplastic BE

    Coverage for ablation of non‑dysplastic BE is not supported by high‑quality outcome data and has cautions:

    Non‑dysplastic BE ablation considerations: Routine endoscopic ablation of non‑dysplastic Barrett's esophagus (ND‑BE) is not recommended because trials have not demonstrated cancer‑risk reduction; procedures often require multiple sessions, recurrences occur, and community effectiveness is uncertain.ND‑BE diagnosis

    Economic models are mixed and clinical trials are needed prior to routine adoption.

    Management by dysplasia and invasion depth

    Coverage and treatment approach commonly follows dysplasia status and lesion depth:

    High‑grade dysplasia (HGD): Endoscopic eradication therapy (eg, EMR, RFA, PDT) is recommended for confirmed HGD; combine EMR with ablation for nodular HGD; endoscopic therapy is preferred over esophagectomy for most patients when invasion is limited to the mucosa.confirmed HGD on histology

    HGD has highest absolute benefit from ablation; surgery reserved for submucosal invasion (T1b) or persistent disease.

    Low‑grade dysplasia (LGD): Management is individualized due to diagnostic variability; RFA is an accepted therapeutic option for confirmed LGD (preferably after expert pathology confirmation) because trials show reduced progression, but selection should focus on patients at higher risk.confirmed LGD by expert pathology

    Phoa et al. multicenter trial showed marked risk reduction after ablation for expert‑confirmed LGD.

    Non‑dysplastic BE (ND‑BE):

    Coverage and clinical use criteria

    Coverage considerations based on current guidelines and evidence:

    When replacement of random biopsies is acceptable: Replacement of the Seattle protocol with targeted imaging‑only approaches is acceptable only if the specific technique and operator performance satisfy ASGE PIVI thresholds and have been validated in the clinical setting.PIVI thresholds

    Evidence to date supports replacement only in selected expert centers.

    Biomarkers and tissue markers: Biomarker panels and tissue‑based assays (eg, TissueCypher, methylation panels, p53 immunostaining) show promise for risk stratification but currently lack sufficient prospective validation and guideline endorsement for routine use; consider investigational or adjunctive in specialized centers.evidence pending larger validation studies

    UpToDate and guideline reviews do not recommend routine clinical use yet.

    Cryotherapy positioning: Cryotherapy (liquid nitrogen or balloon cryoablation) has acceptable feasibility and eradication rates in observational series and is commonly used as salvage therapy after RFA failure; evidence is insufficient to support cryotherapy as routine first‑line ablation over RFA.

    Coverage-related evidence and positioning

    Evidence‑based positioning and considerations

    Preferred ablation sequence: Radiofrequency ablation (RFA) is the preferred first‑line endoscopic ablative therapy for dysplastic Barrett's esophagus based on randomized trial evidence; cryotherapy is principally a salvage option after inadequate response to RFA.

    Shaheen and others support RFA as first choice; cryotherapy evidence remains limited.

    Cryotherapy evidence summary: Systematic reviews and meta‑analyses report pooled CE‑IM and CE‑D rates for various cryotherapy modalities (CE‑IM ~56–86%, CE‑D/CE‑N often high) with feasibility ~95% and overall adverse event rates around 4–12.5%; heterogeneity and lower CE‑IM versus RFA in some series limit conclusions.

    Data are from nonrandomized and heterogeneous studies; comparative trials needed.

    FISH and cytogenetics: FISH on esophageal brushings detects chromosomal abnormalities that correlate with increasing dysplasia; polysomy (eg, 10% cells) associates with higher short‑term progression risk but requires larger prospective validation and is not yet guideline endorsed.polysomy 10% cells

    Evidence summaries for emerging diagnostic/screening modalities

    Evidence summaries and implications for clinical use:

    FISH utility: Single‑ and multi‑institution studies suggest FISH polysomy correlates with increasing dysplasia and may distinguish HGD/EA when approximately 10% of cells show polysomy (reported sensitivity ~80% and specificity ~88%), but guideline endorsement and large prospective validation are lacking.polysomy >=10% cells

    ACG guideline does not currently recommend FISH for routine management.

    Methylated DNA markers / EsoGuard: Methylated DNA marker panels applied to tissue, brushings, or capsule‑sponge specimens show high AUCs in early studies and feasible sampling with Cytosponge, but clinical effectiveness, implementation, and guideline support remain unestablished pending larger validation studies.

    Iyer et al. and others report promising diagnostic AUCs; corroboration needed.

    OCT / VLE implications: OCT and volumetric laser endomicroscopy (VLE) show high lesion‑level sensitivity in pooled analyses and registry data indicate improved neoplasia detection as an adjunct to white‑light endoscopy, but limitations include nonstandardized protocols, interpretation variability, and need for prospective studies to define incremental benefit and cost‑effectiveness.

    Cytosponge screening considerations

    Contextual considerations identified in economic and implementation analyses

    Cytosponge implementation context: Cytosponge‑TFF3 increased BE detection in the BEST3 trial but also generated additional endoscopies and some false positives; cost‑effectiveness modeling favored one‑off screening in trial populations though uncertainty remains about optimal target age, frequency, and population selection.age >=50 and >=6 months acid‑suppressant use (trial criteria)

    Implementation studies (eg, DELTA) and further modeling are ongoing.

    Volumetric laser endomicroscopy (VLE) — evidence summary

    Findings from registry, ex vivo studies, and meta‑analysis

    VLE performance and limitations: Registry data (n≈1,000) report that VLE identified additional areas of concern not seen on white‑light endoscopy in ~59% of procedures and improved neoplasia diagnostic yield by ~55% as an adjunct; meta‑analyses report lesion‑level sensitivities in the mid‑80s with variable specificity, but nonstandardized imaging and interpretation, lack of central pathology, and potential over‑calling limit generalizability.

    Further prospective studies needed to define incremental diagnostic yield and cost‑effectiveness.

    Biomarkers and tissue-based tests (TissueCypher, serum markers, epigenetics)

    Evidence on molecular assays for detection or risk stratification

    TissueCypher and serum markers: Multiplex tissue platforms (eg, TissueCypher) and serum biomarker panels have shown preliminary ability to distinguish HGD/EAC from non‑dysplastic BE in retrospective and small cohort studies but are limited by retrospective design, small samples, and lack of prospective phase IV validation.

    Not yet recommended for routine surveillance decisions by major guidelines.

    Methylation panels and Esopredict: Methylation‑based biomarker panels (eg, Esopredict) demonstrated AUCs ≈0.84 in retrospective validations for predicting progression, indicating potential utility for risk stratification but requiring prospective multi‑center validation before routine clinical use.

    Current evidence insufficient for guideline endorsement (NCCN/ACG).

    Genetics / Polygenic risk scores

    GWAS and PRS research context

    Genetic risk assessment: Genome‑wide association studies have identified multiple germline variants associated with BE/EAC; polygenic risk scores (PRS) modestly improve reclassification versus non‑genetic models but the incremental discriminatory gain is insufficient to alter clinical decision‑making at present.

    Further work on diverse populations and functional validation needed before clinical application.

    Artificial intelligence for detection of early neoplasia

    Diagnostic performance from systematic review/meta‑analysis

    AI diagnostic performance: Meta‑analysis of 12 studies (1,361 patients; 532,328 images) reported pooled sensitivity ~90.3% and specificity ~84.4% (SROC AUC 0.94) for AI detection of early Barrett's neoplasia, but prospective RCTs across diverse histopathologic subtypes are required before routine clinical adoption.

    High pooled accuracy on images; clinical impact on outcomes not yet established.

    Evidence summaries and implications for coverage

    AI evidence summary and coverage implications: AI models demonstrate high pooled sensitivity and specificity for detecting early Barrett's neoplasia but lack prospective outcome‑based RCTs; cautious adoption as adjunctive tools is suggested pending validation.

    May warrant evaluation in expert centers and prospective studies prior to broad coverage.

    WATS incremental yield: Adding WATS/WATS3D to Seattle‑protocol forceps biopsy increases dysplasia detection (pooled RR ≈1.7) with absolute benefit dependent on baseline dysplasia prevalence (NNT ≈8 in high‑prevalence cohorts, up to ≈166 in low‑prevalence cohorts).

    Clinical significance of WATS‑only findings is uncertain due to limited reconfirmation data; confirmatory biopsy recommended.

    WATS3D limitations: Meta‑analyses show high heterogeneity for WATS3D incremental yield and limited reconfirmation by forceps biopsy; follow‑up endoscopic histology is needed to establish clinical relevance of WATS‑only dysplasia findings.

    May prompt requirement for confirmatory forceps biopsy prior to therapeutic interventions.

    Aetna lists a broad set of interventions and diagnostic tests as experimental/investigational for Barrett's esophagus when their effectiveness for BE indications has not been established. These include ablative or surgical procedures such as argon plasma coagulation (APC), cryotherapy/cryoablation, photodynamic therapy (PDT), laser therapy, multi‑polar electrocoagulation, ultrasonic therapy, and more invasive operations (eg, gastrectomy, bariatric surgery). A variety of emerging diagnostics and platforms are likewise considered investigational for BE management in this policy, including artificial intelligence for early neoplasia detection, FISH assays, biomarker panels and methylation DNA assays (eg, EsoGuard/Envisage-like tests), Cytosponge and other capsule‑sponge sampling approaches, confocal laser endomicroscopy, optical coherence tomography/volumetric laser endomicroscopy, and multiplex tissue‑based assays (eg, TissueCypher).

    CPT/HCPCS/ICD code groupings referenced in the policy reflect these technologies and procedural options (for example, codes for endoscopic ablation and EMR, porfimer sodium injection, methylation assay codes such as 0108U, 0114U, 0398U, and a notation that some codes or HCPCS (eg, Cytosponge) have no specific code or are not covered for listed indications).

    The policy highlights that some endoscopic ablation indications remain experimental and, where cancer‑prevention effectiveness is unproven, use should be limited to clinical trials or specialist centers. Reviews and guideline assessments note that while PDT and RFA have trial data in HGD, many ablative modalities lack sufficiently robust long‑term outcome data to justify widespread adoption outside research settings or expert referral centers.

    Authors and guideline bodies emphasize restricting experimental ablation approaches to controlled study environments or experienced centers to ensure adequate patient selection, standardized protocols, expert pathology review, and appropriate follow‑up data collection.

    Aetna and cited reviews conclude that routine ablative therapy for non‑dysplastic Barrett's esophagus (ND‑BE) is not supported by definitive evidence of cancer‑risk reduction. Published analyses note the low absolute lifetime risk of progression for ND‑BE, the need for multiple treatment sessions, recurrence of intestinal metaplasia after ablation, and limited generalizability of trial outcomes performed in expert centers.

    Because large, long‑term trials demonstrating cancer‑prevention benefit are lacking and recurrence/sub‑squamous metaplasia remain concerns, the policy does not endorse routine ablation of ND‑BE outside research or highly selected circumstances.

    The policy describes ablation or endoscopic mucosal resection (EMR) of metaplastic epithelium with or without low‑grade dysplasia (LGD) as experimental when performed outside controlled studies. Bremholm et al. and other reviewers specifically note that ablation or mucosal resection for metaplasia (with or without LGD) is considered investigational and should not be routinely performed outside clinical trials or specialist programs.

    For dysplastic lesions that meet guideline criteria (eg, confirmed HGD), EMR and ablation remain therapeutic options; however, ablation of metaplasia alone without clear dysplastic indication is not recommended outside research contexts.

    Advanced imaging modalities and biomarker panels are described as adjunctive tools but should not replace high‑definition white‑light endoscopy plus Seattle 4‑quadrant random biopsies unless the technique and operator performance have demonstrated ASGE PIVI–level performance. PIVI thresholds require a per‑patient sensitivity of at least 90%, a negative predictive value of at least 98%, and a specificity of at least 80% to justify omission of random biopsies.

    Systematic reviews and guideline statements indicate that most advanced imaging (eg, CLE, OCT/VLE) and biomarker approaches have not consistently met these thresholds in community practice and therefore cannot supplant standard surveillance protocols.

    The available evidence does not support cryotherapy as the preferred first‑line therapy for treatment‑naïve Barrett's esophagus with dysplasia. Systematic reviews and meta‑analyses report promising eradication rates for cryotherapy (including liquid nitrogen and balloon cryoablation) but studies are generally small, observational, heterogeneous, and often include RFA‑refractory cohorts.

    Consequently, the policy notes that cryotherapy should not be considered first‑line over radiofrequency ablation (RFA) in routine practice until high‑quality prospective comparative data demonstrate equivalent or superior outcomes; cryotherapy is most commonly positioned as a salvage option after RFA failure.

    Major guideline reviews and this policy do not endorse tests such as FISH, methylated DNA marker panels (eg, EsoGuard/Envisage‑type assays), or optical coherence tomography (OCT) as standard management tools for Barrett's esophagus at present. Single‑center and preliminary studies suggest these technologies may detect chromosomal abnormalities or methylation signatures associated with dysplasia, but evidence remains insufficient for routine clinical use.

    Aetna therefore characterizes these assays and imaging modalities as investigational for BE indications pending larger prospective validation and guideline endorsement.

    The policy cites research showing that specific mitochondrial DNA deletions (5 kb and 7.4 kb) were not associated with progression to Barrett's esophagus or esophageal adenocarcinoma in examined specimens. These findings do not support use of such mtDNA deletions as clinical markers for BE detection or risk stratification, and the policy treats these deletions as non‑supportive for routine diagnostic application.

    The National Comprehensive Cancer Network's practice guideline for esophageal cancers does not mention DNA methylation assays as a management tool, which the policy interprets as an absence of guideline support for routine clinical use of DNA methylation testing in BE management. This lack of guideline endorsement underlines the need for further prospective validation before methylation assays are adopted into standard practice.

    The policy emphasizes recurrent evidence limitations across emerging biomarker and imaging studies: many reports are limited by small sample sizes, lack of pre‑specified discovery sample sizes, single‑center designs, and absence of large prospective validation cohorts. Authors consistently call for larger, prospective, multi‑institutional studies to validate promising methylation panels, protein or tissue biomarker platforms, and combinations of advanced imaging with biomarker assays before these approaches can be considered for routine clinical decision making.

    Clinical Policy Bulletins such as this are administrative guidance documents developed to assist in plan benefit administration; they do not constitute offers of coverage or medical advice and provide only a partial, general description of plan or program benefits. Treating providers remain responsible for clinical care decisions, and specific coverage determinations depend on the member's benefit plan terms and any applicable prior authorization criteria.

    The policy explicitly references certain tests and codes as not covered or not supported for the listed BE indications. Examples include methylation assay coding (eg, 0386U described as not covered for the listed indications), capsule‑sponge/Cytosponge approaches (noted as having no specific HCPCS code and with downstream endoscopy implications), and other named laboratory and imaging codes in the CPT/HCPCS listings that reflect investigational status for BE management. Providers should reference the policy's coding section when submitting claims for these technologies.

    The policy reiterates that the routine ablation of non‑dysplastic Barrett's esophagus has uncertain value and is not recommended for the general population of patients with ND‑BE. Pooled analyses and economic reviews cited in the background indicate that, although ablation can eradicate metaplasia in many patients, there is insufficient evidence that routine ablation reduces cancer incidence or is cost‑effective across unselected ND‑BE cohorts. As a result, ablation for ND‑BE is not considered medically necessary in routine practice.

    Consistent with the above, the policy states that routine endoscopic ablation for non‑dysplastic BE is not medically necessary given the lack of definitive evidence for cancer‑risk reduction, the need for multiple sessions, recurrence risk, and the low absolute progression risk in ND‑BE populations. Surveillance rather than ablation remains the recommended approach for most patients with ND‑BE.

    Specifically, the policy indicates that routine radiofrequency ablation (RFA) for the general population of patients with non‑dysplastic Barrett's esophagus is not recommended. Although RFA has strong trial evidence supporting eradication of dysplasia and intestinal metaplasia in dysplastic BE, its effectiveness for primary cancer prevention in ND‑BE has not been demonstrated to justify broad application.

    The policy cautions against substituting advanced imaging modalities (for example, confocal laser endomicroscopy or other targeted imaging) for the Seattle 4‑quadrant random biopsy protocol unless the modality plus operator performance have been validated to meet ASGE PIVI performance thresholds (per‑patient sensitivity ≥90%, NPV ≥98%, specificity ≥80%). Systematic reviews show that many advanced imaging technologies and real‑world operator performance have not consistently met these criteria, so omission of random biopsies is not supported except in validated, expert settings.

    The policy notes that routine adoption of novel cryotherapy devices and techniques as first‑line therapy is unsupported without prospective comparative data. Although balloon cryoablation and liquid‑nitrogen cryo‑spray show promising feasibility and eradication rates in small series and meta‑analyses, the evidence is heterogeneous and largely observational; therefore these technologies remain investigational as first‑line modalities until larger, well‑conducted comparative studies are available.

    Technologies such as FISH, EsoGuard / methylated DNA markers (MDMs), and OCT/VLE are described in the policy as investigational for routine BE management. While individual studies report encouraging diagnostic performance (eg, FISH polysomy thresholds distinguishing HGD/EA), the policy emphasizes that guideline bodies and systematic reviews have not endorsed these modalities as standard‑of‑care and larger prospective validation is required before routine clinical adoption.

    Overall, the policy concludes that currently available biomarker tests and tissue‑based risk stratification platforms are unproven for routine management of Barrett's esophagus. Authoritative clinical reviews and guideline statements do not recommend routine use of these biomarkers for surveillance or therapeutic decision making, and the policy treats them as investigational until validated in larger prospective studies.

    The policy summarizes analyses showing that WATS/WATS3D increases dysplasia detection compared with forceps biopsy alone, but the clinical significance of WATS‑only findings remains uncertain because reconfirmatory histology and long‑term follow‑up data are limited. Increased detection without consistent confirmatory biopsies makes it difficult to determine whether WATS‑identified dysplasia should drive therapy; the policy therefore views WATS findings cautiously and supports confirmatory forceps biopsy and follow‑up endoscopy to establish clinical relevance.

    Combination approaches such as autofluorescence imaging (AFI) coupled with biomarker panels have not been prospectively examined in large cohorts. The policy notes that early studies are exploratory and that authors call for larger prospective studies to determine whether combined imaging‑biomarker strategies improve risk stratification or clinical management beyond existing approaches. Until such trials are completed, these combined techniques remain investigational.

    Coding references and code-level requirements

    CPT/HCPCS/Other codes referencedmixed
    43100Excision of lesion, esophagus, with primary repair; cervical approach.
    43101Excision of lesion, esophagus; thoracic or abdominal approach.
    43107Total or near esophagectomy, without thoracotomy; with pharyngogastrostomy or cervical esophagogastrostomy, with or without pyloroplasty (transhiatal).
    43108With colon interposition or small intestine reconstruction, including intestine mobilization, preparation, and anastamosis(es).
    43112Total or near esophagectomy, with thoracotomy; with pharyngogastrostomy or cervical esophagogastrostomy, with or without pyloroplasty.
    43113With colon interposition or small intestine reconstruction, including intestine mobilization, preparation, and anastamosis(es).
    43116Partial esophagectomy, cervical, with free intestinal graft, including microvascular anastamosis, obtaining the graft and intestinal reconstruction.
    43117Partial esophagectomy, distal two-thirds, with thoracotomy and separate abdominal incision, with or without proximal gastrectomy; with thoracic esophagogastrostomy, with or without pyloroplasty (Ivor Lewis).
    43118With colon interposition or small intestine reconstruction, including intestine mobilization, preparation, and anastamosis(es).
    43121Partial esophagectomy, distal two-thirds, with thoracotomy only, with or without proximal gastrectomy, with thoracic esophagogastrostomy, with or without pyloroplasty.
    1–10 of 56
    1/6
    ICD-10 codesICD-10
    K22.710Barrett's esophagus with low grade dysplasia.
    K22.711Barrett's esophagus with high grade dysplasia.
    K22.719Barrett's esophagus with dysplasia, unspecified.
    K22.70Barrett's esophagus without dysplasia (not covered for indications listed).
    C15.3-C15.9Malignant neoplasm of esophagus (not covered for indications listed).
    LGD confirmation requirement
    RequirementHistologic confirmation of low-grade dysplasia (LGD) on 2 or more endoscopies performed at least 3 months apart.
    PurposeEnsures reproducible diagnosis consistent with trial selection and reduces misclassification from inter-observer variability.
    Documentation neededPathology reports from the 2+ endoscopies documenting LGD; expert gastrointestinal pathologist confirmation is recommended.
    PIVI performance thresholds
    Sensitivity thresholdPer-patient sensitivity ≥90% for detection of high-grade dysplasia or early adenocarcinoma.
    Negative predictive value (NPV)

    Authorization, documentation, and operational guidance

    Documentation Required

    Expert-pathologist confirmation recommended

    Expert gastrointestinal pathology confirmation is recommended for any diagnosis of low-grade dysplasia (LGD) prior to authorization of endoscopic eradication therapy (EET). Document that LGD was confirmed by an expert pathologist and include prior surveillance history (number and dates of endoscopies/biopsies). Patients without expert-pathologist confirmation of LGD may not meet selection criteria used in major trials and may be ineligible for coverage of RFA for LGD.

    • Require documentation of expert-pathologist review for LGD cases
    • If expert confirmation absent, note potential denial or need for additional confirmatory biopsies
    Prior Authorization

    Prior authorization for confirmatory endoscopy

    If Cytosponge-TFF3 testing is used and returns a positive result, prior authorization should document the positive result and the referral for confirmatory diagnostic endoscopy. Note that offering Cytosponge in screening will increase the number of confirmatory endoscopies; provide justification when seeking coverage.

    Background and policy context

    Barrett's esophagus is a premalignant condition in which the normal squamous epithelium of the distal esophagus is replaced by metaplastic columnar epithelium, typically related to chronic gastroesophageal reflux disease. Risk stratification and management depend primarily on histologic assessment of dysplasia (no dysplasia, low‑grade dysplasia, or high‑grade dysplasia), and therapeutic options range from surveillance and acid‑suppression to endoscopic eradication therapies or surgical resection depending on dysplasia grade and invasion depth.

    Definitions and key terms

    Short-segment vs long-segment BE
    Short-segment BEDefined as less than 2–3 cm of metaplastic epithelium above the esophago-gastric junction.
    Long-segment BEDefined as greater than 2–3 cm of metaplastic epithelium above the esophago-gastric junction.
    Clinical noteEmphasis is often placed on long-segment BE because it is reportedly associated with higher adenocarcinoma risk, though some studies show similar cancer incidence between short- and long-segment BE.
    Surveillance recommendations (per ACG cited)
    No dysplasiaIf two consecutive endoscopic biopsies show no dysplasia, follow-up endoscopy is recommended at 3 years (ACG guidance).
    Confirmed LGDFor confirmed low-grade dysplasia, consider annual endoscopy until no dysplasia is documented.
    Policy Summary
    PayerAetna
    PolicyBarrett's Esophagus
    Policy CodePolicy 0728
    Change TypeNo material clinical or coverage changes
    Effective DateOct 13, 2006
    Last ReviewAug 2, 2023
    Next Review DateAug 8, 2024
    Key ActionDocument histologic confirmation of low-grade dysplasia on two or more endoscopies at least 3 months apart to support medical necessity for radiofrequency ablation.
    SourceLink
    On This Page
    Coverage criteria and evidence-based positioningCoding references and code-level requirementsAuthorization, documentation, and operational guidanceBackground and policy contextDefinitions and key terms
    Routine ablation is not supported; continued endoscopic surveillance per guidelines is the standard; if ablation performed, surveillance must continue because recurrence and subsquamous metaplasia may persist.
    ND‑BE diagnosis

    Low annual progression risk and limited evidence of benefit from ablation.

    Invasive disease staging: Lesions with evidence of submucosal invasion (T1b) or higher carry increased nodal metastasis risk and generally warrant surgical management rather than endoscopic therapy.evidence of submucosal invasion

    Esophagectomy is standard when invasion beyond the mucosa is present.

    RFA preferred first‑line

    Meta‑analyses report heterogeneous results; RCTs comparing cryotherapy to RFA are lacking.

    Preliminary sensitivity/specificity reported; further multi‑institutional studies required.

    Rodriguez et al. meta‑analysis reports pooled sensitivity/specificity for VLE/OCT.

    Cytosponge screening: BEST3 randomized trial showed offering Cytosponge‑TFF3 to primary‑care patients on acid suppressants aged ≥50 increased BE detection ~10‑fold versus usual care, led to additional endoscopies for positive tests, and economic modeling suggested one‑off screening could be cost‑effective (ICER ≈ £5,500/QALY), but implementation and downstream resource implications require consideration.trial eligibility: age ≥50 and acid‑suppressant use ≥6 months

    Positive Cytosponge tests in the trial were followed by confirmatory endoscopy.

    Methylation tests limitations: Methylation‑based biomarker panels show promising AUCs for progression prediction in retrospective studies but lack prospective phase IV validation and guideline endorsement; NCCN and other guidelines do not currently recommend DNA methylation testing for routine management.

    Further validation required before coverage for surveillance decisions.

    NPV ≥98% required before replacing Seattle 4-quadrant biopsy protocol.
    Specificity thresholdSpecificity ≥80% for targeted imaging techniques to substitute random biopsies.
    • Attach Cytosponge test result (TFF3 positive) and referral note for endoscopy
    • Document clinical rationale for proceeding to endoscopy after Cytosponge
    Prior Authorization

    Prior authorization recommended for adjunctive advanced imaging

    Use of adjunctive advanced imaging (e.g., volumetric laser endomicroscopy [VLE], OCT) should be accompanied by prior-authorization documentation that includes prior diagnostic testing, rationale for the adjunctive imaging, and how results will change management. Advanced imaging cannot generally replace the Seattle protocol unless the operator has documented meeting PIVI performance thresholds.

    • Provide prior diagnostic biopsy results and indication for adjunctive imaging (e.g., unexplained suspicion on white-light endoscopy)
    • If claiming replacement of Seattle protocol, include documentation that operator met PIVI thresholds (sensitivity ≥90%, NPV ≥98%, specificity ≥80%)
    Prior Authorization

    WATS/WATS3D may require prior authorization

    Wide-area transepithelial sampling (WATS/WATS3D) may increase dysplasia detection but the clinical significance of WATS-only dysplasia is uncertain. Prior authorization may be appropriate; when submitted, include concurrent forceps biopsy results and plan for confirmatory histology.

    • If coverage requested based on WATS-only positive findings, include plan for confirmatory forceps biopsy and subsequent management
    • Document whether WATS was adjunctive to standard four-quadrant biopsies
    Note

    Prior authorization not specified

    Some sections of the evidence base and administrative content do not specify prior-authorization or billing requirements. In these cases, follow standard payer rules; include complete clinical documentation when requesting authorization.

    • No explicit prior authorization rule in certain study descriptions — rely on payer-specific prior auth guidelines
    • Provide full clinical records when in doubt
    Denial Risk

    Denial triggers — experimental/investigational interventions

    Interventions and technologies described in this policy as experimental or investigational (and therefore potential denial triggers) include argon plasma coagulation (APC), cryotherapy/cryoablation (when used outside accepted salvage indications), optical coherence tomography (OCT)/VLE without validated protocols, Cytosponge for routine surveillance, Barrett’s esophagus FISH assays, DNA-methylation prognostic assays, and other novel biomarkers and imaging modalities.

    • List of examples: APC, cryotherapy/cryoablation (except where listed as medically necessary/salvage per policy), OCT/VLE without validated protocol, Cytosponge for screening outside specified pathways, FISH assays (MolDX)
    • Experimental coding/status noted in CPT/HCPCS sections may be not covered
    Denial Risk

    Uncertain long-term efficacy

    Long-term efficacy evidence is limited or uncertain for many ablative techniques other than RFA and PDT. When prior authorization is sought for interventions lacking long-term data, include supportive evidence and rationale; absence of such evidence may result in denial.

    • RFA and PDT have longer-term data; many newer or less-studied modalities lack proven cancer-risk reduction
    • Document long-term follow-up data when available to support requests
    Denial Risk

    Patients without expert-pathologist confirmation

    Patients diagnosed with LGD who lack expert-pathologist confirmation should have additional confirmatory biopsies or expert review before consideration for ablation. Trial selection criteria required expert confirmation; absence of this may preclude coverage for RFA in LGD.

    • Document steps taken to obtain expert pathology review or repeat endoscopy/biopsy
    • Note that many patients initially reported as LGD are downgraded on expert review
    Documentation Required

    Replacement of Seattle protocol — performance expectation

    Advanced imaging techniques should not replace the Seattle 4-quadrant biopsy protocol unless the operator demonstrates validated performance that meets PIVI thresholds. Documentation of operator training, validation, and per-operator performance (sensitivity/NPV/specificity) is expected when using imaging to supplant random biopsies.

    • Provide operator performance metrics and validation studies if claiming replacement of Seattle protocol
    • If PIVI thresholds are not met, include standard 4-quadrant biopsies in the plan
    Denial Risk

    Insufficient comparative evidence

    Novel ablative tools and imaging technologies without robust comparative evidence versus established therapies are considered investigational. Prior-authorization requests for such technologies should include high-quality comparative data; lacking that, requests may be denied.

    • Provide prospective comparative studies if available
    • Otherwise, expect investigational determination and potential denial
    Prior Authorization

    Confirmatory endoscopy after positive Cytosponge

    BEST3 and other Cytosponge trials demonstrated increased detection of Barrett's esophagus but also led to increased endoscopies. Prior-authorization submissions after Cytosponge positives should include the test result, referral documentation, and planned diagnostic/therapeutic steps.

    • Attach Cytosponge-TFF3 positive report and clinical referral note
    • Document anticipated downstream procedures (endoscopy, biopsy, therapy)
    Denial Risk

    Evidence limitations may trigger denial

    Limitations in the evidence base (lack of standardized protocols, short follow-up, operator experience concentrated in referral centers) may prompt denial or requests for additional justification. When requesting authorization for modalities with limited supportive data, include protocol details and follow-up plans.

    • Provide standardized imaging/biopsy protocol when available
    • Include planned follow-up interval and surveillance strategy
    Denial Risk

    Uncertain clinical significance and limits of WATS-only findings

    Clinical significance of WATS-only detected dysplasia is uncertain; prior-authorization or coverage may require confirmatory forceps biopsies and documentation of subsequent histology to guide management decisions.

    • If WATS-only dysplasia reported, submit plans for confirmatory FB biopsies and targeted management
    • Document any available re-confirmation histology results
    Note

    No explicit authorization or billing requirements in some source text

    Some study reports and administrative sections describe research findings without explicit billing or authorization rules. For operational questions, follow payer-specific prior authorization and coding policies; include full clinical documentation when requesting coverage.

    • No step-therapy or billing rules presented in parts of the source — use standard payer procedures
    • When in doubt, include complete clinical records and rationale
    Note

    Not applicable content in this section

    This section contains background, evidence summaries, and administrative notes that are informational and not actionable coverage rules. Use the provider-action callouts above for authorization and documentation requirements.

    • Policy history and additional information are administrative — see header for effective and next review dates
    Documentation Required

    Documentation for RFA in LGD

    For radiofrequency ablation (RFA) in LGD, document histologic confirmation of LGD on two or more endoscopies at least 3 months apart. Include grade of dysplasia, dates/results of prior surveillance endoscopies, and the indication for ablation in authorization requests.

    • Provide ≥2 endoscopy/biopsy reports showing LGD separated by ≥3 months
    • Include prior surveillance history and rationale for RFA
    Documentation Required

    Required clinical documentation

    Required clinical documentation for authorization requests should include dysplasia grade, prior treatments, prior surveillance results, indication for ablation, acid-suppression therapy details, and expert-pathology reports where applicable.

    • List required items: dysplasia grade, dates/results of prior endoscopies/biopsies, prior endoscopic/surgical treatments, current PPI regimen and response, expert pathology consultation reports
    Documentation Required

    Documentation of histologic confirmation

    Histologic confirmation of intestinal metaplasia and accurate dysplasia classification (LGD versus HGD) is necessary to guide management and prior-authorization decisions. Include biopsy pathology reports and any expert second opinions in submissions.

    • Attach pathology reports confirming intestinal metaplasia and dysplasia grade
    • Include expert second-opinion pathology when obtained
    Documentation Required

    Operator validation and performance documentation

    When advanced imaging or replacement of standard protocols is claimed, document operator validation, training, and performance meeting PIVI thresholds or an accepted validated-equivalent. Include center volume or operator experience if relevant.

    • Provide operator-level performance metrics (sensitivity, NPV, specificity) or evidence of having met PIVI thresholds
    • Document endoscopist volume and advanced imaging experience
    Documentation Required

    Required clinical documentation for cryotherapy cases

    For cryotherapy cases, authorization submissions should include prior treatment history (number and type of prior ablation sessions, including RFA), histopathology, and the number of prior sessions. Cryotherapy is primarily considered salvage therapy after RFA failure; primary use may require stronger justification.

    • Document number and dates of prior RFA or other ablation sessions
    • Attach histopathology confirming persistent dysplasia or IM
    • Specify whether cryotherapy is primary or salvage therapy
    Documentation Required

    Required documentation for FISH assay

    When FISH assays (e.g., MolDX) are submitted for consideration, include indication, specimen type (brush cytology or biopsy), and any concurrent biopsy/histology results. FISH is considered investigational by this policy context and may be denied without evidence of clinical utility in the specific case.

    • Provide specimen type and concurrent histology/biopsy results
    • Include rationale for FISH use and how results will affect management
    Documentation Required

    Document Cytosponge result and referral for endoscopy

    If Cytosponge-TFF3 is used, document the Cytosponge result and the referral for endoscopy. Because Cytosponge screening increases endoscopy rates, include clinical justification for proceeding to endoscopy when seeking coverage for downstream procedures.

    • Attach Cytosponge-TFF3 result and referral note
    • Provide justification for confirmatory endoscopy and planned next steps
    Documentation Required

    Required supporting documentation

    Supporting documentation for registry or post-market device use should include the protocol used, imaging interpretation criteria, tissue acquisition strategy, and follow-up plans. Many registry reports lacked standardized protocols; include these details when seeking authorization.

    • Provide imaging and biopsy protocol, image interpretation criteria, and planned surveillance intervals
    • If participating in a registry, include registry protocol and governance information
    Documentation Required

    Assay documentation

    For molecular and multi-gene assays (e.g., DNA methylation panels, Esopredict, multi-gene methylation tests), describe development, validation, intended use population, specimen types, and how results will alter surveillance or treatment. These assays are generally considered investigational unless validated with demonstrated clinical utility.

    • Include validation studies, intended clinical use, and evidence linking assay results to management changes
    • If assay results will change surveillance intervals or trigger ablation, document the decision algorithm
    Note

    Policy history and administrative notes

    Policy history, review dates, and administrative notes are provided in the Additional Information and Policy History sections. These are administrative and do not substitute for clinical documentation required for prior authorization.

    • Effective date: 2006-10-13; Next Review: 08/08/2024
    • Use clinical callouts above for authorization actions
    Note

    Therapy escalation and surgical/treatment sequencing considerations

    Therapy escalation should follow standard sequencing: optimize acid suppression and anti-reflux measures, perform EMR for visible/nodular lesions prior to ablative monotherapy, consider combined EMR + ablation for nodular HGD, reserve esophagectomy for selected candidates or multifocal/submucosal invasion, and consider endoscopic therapy (RFA preferred) over esophagectomy for most HGD when feasible.

    • Optimize PPI therapy prior to ablation and document regimen and response
    • EMR for visible lesions should be performed before ablative monotherapy
    • Esophagectomy remains gold standard for selected patients (e.g., submucosal invasion)
    Note

    Prefer RFA before cryotherapy; RFA preferred first-line before cryotherapy

    Evidence and guideline summaries favor radiofrequency ablation (RFA) as the preferred first-line endoscopic ablative therapy for dysplastic BE (HGD and selected LGD). Cryotherapy is generally considered a salvage option after RFA failure and primary cryotherapy requests should include robust justification.

    • RFA preferred first-line for dysplastic BE (HGD and selected LGD)
    • Cryotherapy primarily salvage; primary cryotherapy requires stronger evidence and may be investigational
    Note

    No step therapy rules presented / Not specified

    No specific step-therapy rules (e.g., mandatory trials of alternate modalities before ablation) are presented in the source text. Coverage decisions should follow payer criteria and the clinical documentation requirements outlined above.

    • No explicit step-therapy algorithms provided in this section
    • Follow payer-specific prior authorization and clinical-necessity criteria
    Note

    Suggested stepwise testing approach

    A suggested stepwise testing approach described in the evidence includes triage with non-endoscopic tests (e.g., Cytosponge) followed by confirmatory endoscopy for positives, and use of adjunctive imaging or molecular assays as add-ons with documented impact on management.

    • Cytosponge triage → confirmatory endoscopy if positive
    • Adjunctive imaging or assays require evidence they will change management and should be documented
    Denial Risk

    Because the clinical significance of WATS-only findings is uncertain

    Because the clinical significance of WATS-detected dysplasia (WATS-only) is unclear and reconfirmation rates with forceps biopsy are limited, authorization requests based solely on WATS findings should include a reconfirmation plan and may be questioned or denied without confirmatory histology.

    • Plan for follow-up forceps biopsies to confirm WATS-only dysplasia
    • Document management intentions pending reconfirmation
    Billing Rule

    No explicit authorization or billing requirements specified in the source

    No universal authorization/billing instructions are specified in the source; providers should follow payer-specific prior authorization pathways. Include all required clinical documentation (see documentation callouts) when submitting requests.

    • Follow Aetna prior authorization processes and attach complete clinical documentation
    • Claims coding should reference covered CPT/HCPCS only when selection criteria are met
    HGD approachHigh-grade dysplasia warrants repeat endoscopy or intervention depending on extent; focal HGD (<5 crypts) may be followed with 3-month surveillance.
    Photodynamic therapy (PDT)
    DescriptionPhotodynamic therapy (PDT) uses porfimer sodium plus endoscopic light activation (with acid suppression) to ablate Barrett's mucosa.
    Trial evidenceRandomized trial (Overholt et al.) showed PORPDT achieved higher complete HGD ablation (77% vs 39%) and reduced esophageal adenocarcinoma incidence versus omeprazole alone.
    Safety notePDT is associated with treatment-related adverse effects; benefits for long-term cancer prevention remain incompletely defined in some reviews.
    Radiofrequency ablation (RFA)
    MechanismControlled RF energy causes superficial epithelial ablation while sparing deeper layers, allowing neosquamous regeneration.
    EvidenceRandomized controlled trials (AIM/Shaheen et al.) demonstrated high eradication rates of dysplasia and intestinal metaplasia and reduced progression/cancer rates.
    Cryotherapy (spray/liquid nitrogen)
    ModalitiesIncludes liquid nitrogen spray cryotherapy (LNC) and balloon cryoablation devices cleared for endoscopic use.
    Evidence typeEvidence is primarily observational: single-center series, multicenter cohorts, and systematic reviews/meta-analyses with limited randomized data; used often as salvage therapy after RFA failure.
    Argon plasma coagulation (APC)
    TechniqueArgon plasma coagulation (APC) is a non-contact thermal ablation that uses ionized argon gas to coagulate superficial mucosa.
    Efficacy/concernAPC can achieve ablation in some series but studies report microscopic residual (buried) glands and uncertain long-term impact on cancer prevention.
    Comparative dataRandomized and comparative trials show mixed effectiveness versus PDT and other modalities; long-term outcomes remain uncertain.
    Endoscopic mucosal resection (EMR)
    DescriptionEndoscopic mucosal resection (EMR) removes visible superficial lesions endoscopically, permitting histopathologic diagnosis and potentially curative removal.
    LimitationsLarger lesions may require piecemeal resection, limiting margin assessment and complete histologic evaluation.
    CR-IM — Complete eradication of intestinal metaplasia
    DefinitionComplete eradication of intestinal metaplasia (CR-IM) is absence of intestinal metaplasia on surveillance biopsies after therapy.
    MeasurementAssessed by systematic biopsy sampling (eg, 4-quadrant biopsies) of the previously involved segment and reviewed by pathologists.
    Clinical relevanceCR-IM is a key efficacy endpoint in RFA and cryoablation trials and relates to reduced recurrence, though surveillance remains necessary.
    Disease progression rates
    Overall progression rate after RFAAnnualized overall disease progression reported as ~1.37% per patient-year (Shaheen long-term trial).
    LGD-stratified progressionIn subjects with baseline LGD, annual overall progression reported as ~2.04% per patient-year; progression to EAC ~0.51% per year.
    HGD-stratified progressionAmong subjects with baseline HGD, annual overall progression reported as ~0.60% per patient-year and progression to EAC ~0.60% per year.
    AGA definition of Barrett's esophagus
    DiagnosisRequires combined macroscopic (endoscopic) and microscopic (histologic) examination, including dysplasia grading if present.
    Management implicationDysplasia grade guides surveillance intervals and treatment decisions (ND, LGD, HGD distinctions).
    Prague classification
    UseStandardizes reporting of BE segment extent to guide surveillance and treatment planning.
    RequirementRecorded during endoscopy to document baseline segment length for follow-up comparisons.
    PIVI thresholds — ASGE performance expectations
    ContextASGE PIVI performance expectations define minimum characteristics for an imaging technique to replace Seattle 4-quadrant biopsies.
    SensitivityPer-patient sensitivity ≥90% for detecting HGD/early adenocarcinoma.
    NPV and specificityNPV ≥98% and specificity ≥80% required; operator/center validation needed before substitution.
    CE-D / CE-IM definitions
    CE-D definitionComplete eradication of dysplasia (CE-D) indicates no dysplasia detected on post-treatment biopsies.
    CE-IM definitionComplete eradication of intestinal metaplasia (CE-IM) indicates no intestinal metaplasia on surveillance biopsies after therapy.
    Use in studiesCE-D and CE-IM are commonly reported endpoints in RFA and cryoablation outcome studies and meta-analyses.
    CE-IM as reported in pooled cryoablation outcomes
    Reported CE-IM in pooled cryoablation outcomesPooled CE-IM rates reported in cryoablation analyses vary (eg, primary-use balloon cryoablation pooled CE-IM ~85.8% in some series; liquid nitrogen pooled CE-IM ~56.5% in other analyses).
    HeterogeneityReported pooled estimates vary across device types and study populations; study quality and heterogeneity are limitations.
    Clinical implicationCE-IM after cryoablation is achievable but may be lower than CR-IM rates reported with RFA in randomized trials; comparative data are limited.
    CE-D / CE-N definitions from cryoablation studies
    CE-D / CE-N definitions in cryo studiesCryoablation studies report CE-D (complete eradication of dysplasia) and CE-N/CE-IM/CE-HGD as outcome measures to describe eradication of neoplasia or dysplasia.
    Outcome variabilityReported CE-D/CE-N rates vary by device, prior treatment status (treatment-naïve vs RFA-refractory), and study design.
    Evidence typeMost cryotherapy evidence derives from observational cohorts and meta-analyses; randomized comparative data are limited.
    Polysomy (FISH) — chromosomal gain definitions
    Polysomy definition (FISH) — generalPolysomy refers to multiple chromosomal gains (eg, ≥3 signals for ≥2 probes) in a cluster of cells and is associated with increasing dysplasia and progression risk.
    Study-specific definitionIn some studies polysomy was defined as ≥4 cells with polysomy (Brankley) or as gain of at least two loci; presence of polysomy correlated with higher risk of EA.
    Clinical implicationPolysomy on FISH in brushings identified patients at higher short-term risk for progression to esophageal adenocarcinoma in high-risk cohorts.
    Polysomy (FISH) threshold used in referenced study (≥10% cells)
    Study thresholdIn the referenced multi-center study, a threshold of ≥10% of cells with polysomy within a specimen was used to differentiate EA/HGD from other pathologies (sensitivity ~80%, specificity ~88%).
    Practical noteThe 10% polysomy cut-point provided discrimination in that dataset but requires further validation in larger cohorts before routine clinical use.
    Specimen typeThreshold applied to endoscopic tissue specimens and brushings analyzed by FISH probes targeting MYC, CDKN2A, ERBB2, and ZNF217.
    Cytosponge-TFF3 — device description and biomarker use
    Device descriptionCytosponge-TFF3 is a non-endoscopic swallowable mesh sponge encased in a gelatin capsule attached to a string; once swallowed and retrieved it collects esophageal cells for biomarker staining (TFF3).
    Implementation noteBEST3 randomized trial evaluated Cytosponge offer in primary care and demonstrated increased BE detection versus usual care, with downstream confirmatory endoscopies and economic analyses.
    EsoGuard / MDMs — methylated DNA marker assay
    Evidence statusEarly studies report promising accuracy (high AUCs) on tissue and sponge/brush specimens but clinical effectiveness and guideline support are limited, requiring further validation.
    Clinical useNot yet established as routine management tools; considered investigational pending larger prospective trials and guideline endorsement.
    Optical Coherence Tomography (OCT)
    ModalityOptical coherence tomography (OCT) is a high-resolution, cross-sectional imaging modality that visualizes esophageal wall layers analogous to 'optical biopsy'.
    CapabilitiesOCT/VLE may identify intestinal metaplasia, sub-squamous IM, dysplasia, and stage early cancer with lesion- and patient-level sensitivities reported across studies.
    Limitations/evidenceAccuracy is variable and may not yet meet thresholds to replace 4-quadrant biopsies; further randomized and cost-effectiveness studies are needed.
    Volumetric laser endomicroscopy (VLE)
    TechnologyVolumetric laser endomicroscopy (VLE) is a second-generation, wide-field OCT-based endoscopic imaging platform providing high-resolution cross-sectional imaging of the esophageal mucosa.
    Clinical findingsRegistry studies report VLE identified additional areas of concern in ~59% of procedures and increased neoplasia diagnostic yield by ~55% as an adjunct to standard endoscopy.
    Evidence limitationsMost data derive from registries and observational studies; standardized imaging protocols, central pathology, and prospective comparative trials are limited.
    Cytosponge — minimally invasive cell collection device
    DeviceCytosponge is a minimally invasive, non-endoscopic cell collection device swallowed in primary care to obtain esophageal cells for biomarker analysis.
    Role in screeningProposed as a primary care triage/screening test to identify patients for confirmatory endoscopy, with BEST3 trial evidence showing increased detection versus usual care.
    Implementation considerationsScreening impact depends on uptake, target age groups, risk-enrichment strategies, and downstream endoscopy capacity; economic models suggest potential cost-effectiveness in selected scenarios.
    Artificial Intelligence for Barrett's neoplasia
    Evidence gapProspective randomized trials across histopathologic subtypes and real-world validation are needed before routine clinical adoption.
    Polygenic risk score (PRS)
    Clinical utilityPRS may modestly improve risk stratification but current discriminatory gains are insufficient to change clinical decision-making; further validation required.
    Research statusDerived from GWAS findings; limited by population diversity and need for functional validation of variants.
    AI in endoscopy — ML image detection
    Reported performancePooled studies show high sensitivity (~90%) and specificity (~84%), but analyses largely derive from retrospective image datasets.
    Implementation noteProspective clinical trials and integration into community endoscopy workflows with performance monitoring are required prior to routine use.
    WATS/WATS3D — wide-area transepithelial sampling
    DescriptionWATS/WATS3D is wide-area transepithelial sampling using abrasive brushings with 3D computer-assisted analysis intended to increase dysplasia detection beyond standard forceps biopsies.
    Intended purposeUsed as an adjunct to Seattle forceps biopsy to improve detection of dysplasia/HGD with reported incremental yields varying by baseline prevalence.
    Evidence limitationsMeta-analyses show increased dysplasia detection but high heterogeneity and limited reconfirmation of WATS-only findings by forceps biopsy; clinical significance of isolated WATS detections remains uncertain.
    DNA methylation tests (Envisage-like)
    Test classDNA methylation tests (Envisage-like) measure methylation patterns in BE/EAC tissues to classify subtypes or predict progression risk.
    EvidenceRetrospective and early validation studies report promising AUCs (~0.84) and candidate marker panels, but prospective phase IV validation and guideline endorsement are lacking.
    SpecimensAssays have been applied to biopsy tissue, esophageal brushings, and capsule sponge specimens (eg, Cytosponge) with variable performance across sample types.
    AFI — autofluorescence imaging
    DefinitionAutofluorescence imaging (AFI) is an advanced endoscopic imaging modality that detects tissue fluorescence differences to highlight suspicious mucosa in BE.
    Intended roleStudied as an adjunct to guide targeted biopsies and to potentially concentrate biomarker sampling, but not established to replace standard surveillance.
    Evidence limitationsCombination of AFI with biomarkers has been examined retrospectively; prospective validation is needed to establish clinical utility.
    Esophageal brushing samples
    Specimen typeEsophageal brushing samples collect cytologic material during endoscopy that can be used for molecular methylation assays and FISH analysis.
    Use caseBrushings have been used with FISH and methylation panels to detect chromosomal abnormalities or methylated markers associated with dysplasia/EAC.
    DocumentationConcurrent forceps biopsy/histology is recommended when interpreting molecular results from brushings to correlate with tissue pathology.
    Policy history
    Last review08/02/2023
    Effective date10/13/2006
    Next scheduled review08/08/2024